Advances in Therapy

, Volume 22, Issue 3, pp 278–283 | Cite as

Treatment of bulimia nervosa with fluvoxamine: A randomized controlled trial

  • W. Milano
  • C. Siano
  • C. Putrella
  • A. Capasso


Bulimia nervosa (BN) is one of the most common eating disorders in industrialized societies. It has been suggested that reduced serotonin activity triggers some of the cognitive and mood disturbances associated with BN. For this reason, the pharmacologic treatment of BN consists mainly of selective serotonin reuptake inhibitors (SSRIs), which have been proven effective. At present, the physiologic bases of this disorder are not yet completely understood. We conducted a randomized controlled trial to verify the efficacy of the SSRI fluvoxamine in patients with a diagnosis of BN. Twelve female outpatients aged 21 to 34 years with a diagnosis of BN-binge purging (as defined by the fourth edition of theDiagnostic and Statistical Manual of Mental Disorders [DSM IV]) were randomly assigned to 2 treatment groups: the fluvoxamine 200 mg/day group and the placebo group. The patients underwent weekly clinical assessments for 12 weeks. At the end of the observation period, there was a statistically significant reduction in the number of binge-eating crises and purging episodes in the fluvoxamine group compared with placebo. In no case was treatment interrupted because of emergent side effects. These findings support the hypothesis that fluvoxamine is well tolerated and effective in reducing binge-eating crises and purging episodes in patients with BN.


bulimia serotonin selective serotonin reuptake inhibitors fluvoxamine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Brambilla F. Aetiopathogenesis and pathophysiology of bulimia nervosa: biological bases and implication for treatment.CNS Drugs. 2001;15:119–136.PubMedCrossRefGoogle Scholar
  2. 2.
    Casacchia M, Mela C, Chiaravalle E, eds. Eating disorders.Clinica Psichiatrica. Aquila, Italy: Universitá dell’Aquila; 2000.Google Scholar
  3. 3.
    American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Arlington, Va: American Psychiatric Association; 1994.Google Scholar
  4. 4.
    Cuzzolaro M, Magnani M. Obesità e disturbi del comportamento alimentare. In: Borsello O, ed.Obesità. Rome, Italy: Kurtis; 1998.Google Scholar
  5. 5.
    Bellodi L, Brambilla F, eds. Eating disorders and obsessive compulsive disorders: an etiopathogenetic link? In:Centro Scientifio Editore. Turin, Italy; 1999:16–44.Google Scholar
  6. 6.
    Brewerton TD. Toward a unified theory of serotonin dysregulation in eating and related disorders.Psychoneuroendocrinology. 1995;20:561–590.PubMedCrossRefGoogle Scholar
  7. 7.
    Ramacciotti C. Terapia farmacologica della bulimia nervosa e del B.E.D. In: Cuzzolaro M, ed.Terapia dei DCA. Rome, Italy: Kurtis; 2000.Google Scholar
  8. 8.
    Liebowitz SF. Brain serotonin and eating behavior.Appetite. 1986;7:1–4.Google Scholar
  9. 9.
    Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects.J Affect Disord. 1998;51:215–235.PubMedCrossRefGoogle Scholar
  10. 10.
    Muller E, Brambilla F.Disordini del Comportamento Alimentare. Milan, Italy: Pythagora Press; 1997.Google Scholar
  11. 11.
    Devane CL. Comparative safety and tolerability of SSRI.Hum Psychopharmacol. 1995;10:185–193.CrossRefGoogle Scholar
  12. 12.
    Henderson M, Freeman CP. A self-rating scale for bulimia: the BITE.Br J Psychiatry. 1987;150:18–24.PubMedGoogle Scholar
  13. 13.
    American Psychiatric Association. Practice guideline for the treatment of patients with eating disorders.Am J Psychiatry. 2000;157(suppl):1–39.Google Scholar
  14. 14.
    Kaye W, Gendall K, Strober M. Serotonin neuronal function and selective serotonin reuptake inhibitors treatment in anorexia and bulimia nervosa.Biol Psychiatry. 1998;44:825–838.PubMedCrossRefGoogle Scholar
  15. 15.
    Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2.Biochem Pharmacol. 1993;45:1211–1214.PubMedCrossRefGoogle Scholar
  16. 16.
    Bertschy G, Vandel S, Allers G, et al. Fluvoxamine-tricyclic antidepressant interactions.Eur J Clin Pharmacol. 1991;40:119–120.PubMedCrossRefGoogle Scholar
  17. 17.
    De Vries MH, Raghoebar M, Mathlener IS, van Harten J. Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects.Ther Drug Monit. 1992;14:493–498.PubMedCrossRefGoogle Scholar
  18. 18.
    Fleishaker J, Hulst L. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine.Eur J Clin Pharmacol. 1994;46:35–39.PubMedCrossRefGoogle Scholar
  19. 19.
    Overmars H, Scherpenisse P, Post L. Fluvoxamine maleate: metabolism in man.Eur J Drug Metab Pharmacokinet. 1983;8:269–280.PubMedCrossRefGoogle Scholar
  20. 20.
    Spigset O, Gramberg K, Hagg S, Soderstrom E, Dahlqvist R. Non-linear fluvoxamine disposition.Br J Clin Pharmacol. 1998;45:257–263.PubMedCrossRefGoogle Scholar
  21. 21.
    Strauss WL, Layton ME, Duger SR. Brain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopy.Am J Psychiatry. 1998;155:380–384.PubMedGoogle Scholar
  22. 22.
    Walczak DD, Apter JT, Halikas JA, et al. The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients.Ann Clin Psychiatry. 1996; 8:139–151.PubMedCrossRefGoogle Scholar
  23. 23.
    Pinto A, Capasso A, Sorrentino L. Experimental animal studies on the hypoglycemic effects of a copalchi extract.Arzneimittelforschung. 1997;47:829–833.PubMedGoogle Scholar

Copyright information

© Health Communications Inc 2005

Authors and Affiliations

  • W. Milano
    • 1
  • C. Siano
    • 1
  • C. Putrella
    • 1
  • A. Capasso
    • 1
  1. 1.Department of Pharmaceutical Sciences Mental Health UnitUniversity of SalernoNaplesItaly

Personalised recommendations